Premium
Life expectancy of patients with chronic nonleukemic myeloproliferative disorders
Author(s) -
Rozman Ciril,
Feliu Evarist,
Giralt Manuel,
Rubio Daniel,
Cortés MaríaTeresa
Publication year - 1991
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19910515)67:10<2658::aid-cncr2820671042>3.0.co;2-c
Subject(s) - medicine , polycythemia vera , essential thrombocythemia , myelofibrosis , population , life expectancy , myeloproliferative disorders , relative survival , survival rate , surgery , epidemiology , bone marrow , cancer registry , environmental health
This study determines, within the frame of current therapeutic possibilities, the impact of chronic nonleukemic myeloproliferative disorders on expected survival. The survival data for 1067 patients (454 with polycythemia vera, 247 with essential thrombocythemia, and 366 with idiopathic myelofibrosis) were collected from 38 Spanish institutions. The actuarial survival probability of each group of patients was compared with that of the age‐matched and sex‐matched control population. The survival of the patients with polycythemia vera and essential thrombocythemia did not differ from that of the control population ( P = 0.92 and, 0.22, respectively), whereas the survival of the patients with idiopathic myelofibrosis was strikingly reduced with respect to the control population ( P = 0.7). Thus, in terms of survival, current therapeutic procedures may be considered as quite satisfactory in patients with polycythemia vera and essential thrombocythemia. On the other hand, due to poor survival of patients with idiopathic myelofibrosis, new therapeutic approaches for this condition are clearly needed.